Gilead Sciences, Inc. (NASDAQ:GILD) Shares Purchased by Knuff & Co LLC

Knuff & Co LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) by 3.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 24,006 shares of the biopharmaceutical company’s stock after purchasing an additional 895 shares during the period. Knuff & Co LLC’s holdings in Gilead Sciences were worth $1,481,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in GILD. Arrowstreet Capital Limited Partnership raised its position in shares of Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock valued at $1,070,232,000 after acquiring an additional 13,764,169 shares in the last quarter. Renaissance Technologies LLC grew its stake in Gilead Sciences by 70.6% during the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after buying an additional 6,410,047 shares during the last quarter. Northern Trust Corp grew its stake in Gilead Sciences by 2.3% during the 2nd quarter. Northern Trust Corp now owns 15,313,169 shares of the biopharmaceutical company’s stock worth $946,506,000 after buying an additional 343,918 shares during the last quarter. Parnassus Investments LLC grew its stake in Gilead Sciences by 8.1% during the 2nd quarter. Parnassus Investments LLC now owns 11,720,556 shares of the biopharmaceutical company’s stock worth $724,448,000 after buying an additional 880,418 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in Gilead Sciences by 9.1% during the 2nd quarter. Deutsche Bank AG now owns 8,950,346 shares of the biopharmaceutical company’s stock worth $553,222,000 after buying an additional 746,049 shares during the last quarter. 78.72% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.9 %

Shares of Gilead Sciences stock opened at $84.02 on Wednesday. The stock has a 50-day moving average price of $85.92 and a 200 day moving average price of $73.22. The company has a market cap of $105.38 billion, a P/E ratio of 31.71, a P/E/G ratio of 0.80 and a beta of 0.45. The company has a current ratio of 1.30, a quick ratio of 1.16 and a debt-to-equity ratio of 1.14. Gilead Sciences, Inc. has a 1 year low of $57.17 and a 1 year high of $89.74.

Gilead Sciences (NASDAQ:GILDGet Rating) last announced its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.44 by $0.46. The firm had revenue of $7.04 billion during the quarter, compared to the consensus estimate of $6.12 billion. Gilead Sciences had a return on equity of 38.51% and a net margin of 12.29%. As a group, analysts expect that Gilead Sciences, Inc. will post 7.08 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, December 29th. Shareholders of record on Thursday, December 15th were given a $0.73 dividend. This represents a $2.92 annualized dividend and a yield of 3.48%. The ex-dividend date was Wednesday, December 14th. Gilead Sciences’s payout ratio is currently 110.19%.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent analyst reports. Morgan Stanley decreased their price target on Gilead Sciences from $81.00 to $80.00 and set an “equal weight” rating for the company in a research note on Tuesday. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their price target for the stock from $76.00 to $91.00 in a research note on Friday, October 28th. BMO Capital Markets increased their price target on Gilead Sciences from $63.00 to $72.00 and gave the stock a “market perform” rating in a research note on Friday, October 28th. Bank of America reissued a “neutral” rating and issued a $85.00 price target on shares of Gilead Sciences in a research note on Tuesday, December 13th. Finally, Cowen upped their price objective on Gilead Sciences from $80.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, November 8th. Nine equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $87.40.

Insiders Place Their Bets

In other Gilead Sciences news, CAO Diane E. Wilfong sold 16,255 shares of the company’s stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $79.25, for a total value of $1,288,208.75. Following the transaction, the chief accounting officer now directly owns 28,333 shares of the company’s stock, valued at approximately $2,245,390.25. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CAO Diane E. Wilfong sold 16,255 shares of the stock in a transaction dated Tuesday, November 1st. The stock was sold at an average price of $79.25, for a total transaction of $1,288,208.75. Following the transaction, the chief accounting officer now owns 28,333 shares of the company’s stock, valued at approximately $2,245,390.25. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Diane E. Wilfong sold 6,416 shares of the stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $83.50, for a total value of $535,736.00. Following the transaction, the chief accounting officer now directly owns 28,333 shares in the company, valued at approximately $2,365,805.50. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

(Get Rating)

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Articles

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.